课题基金 / 基金详情

项目摘要

项目成果

Frederic Barr的其他基金

相似基金

相关文献

中文摘要
翻译
为了扩展我们对融合阳性横纹肌肉瘤(RMS)中12q13-q14扩增的研究,我们使用了来自癌症基因组图谱(TCGA)的数据来比较我们在RMS中的发现与其他癌症类别中该染色体区域的扩增。特别是,我们在多形性胶质母细胞瘤(GBM)、去分化脂肪肉瘤(dLPS)和肺腺癌(LAC)中发现了多例12q13-q14扩增病例。虽然我们之前的研究在25%的pax3 - fox01阳性RMS病例中发现了12q13-q14扩增子,但TCGA数据分析发现12q13-q14扩增子在7%的LAC, 20%的GBM和86%的dLPS中存在。然后,我们使用统计方法来描述每种癌症类别中持续扩增的区域。在该分析中,将扩增区域周围的大基因组区域分成许多间隔,然后在扩增子阳性和扩增子阴性样本中评估每个间隔的拷贝数。然后用Bonferroni校正的Mann-Whitney U检验评估每个区间的显著拷贝数差异。该分析在四种癌症类别中确定了一个共同的0.24 Mb扩增区域(包含13个基因,包括CDK4)。除了常见扩增区域外,融合阳性RMS的扩增区域向着丝粒方向延伸,GBM、dLPS和LAC的扩增区域向端粒方向延伸。为了评估这些扩增事件的表达后果,我们分析了每种癌症类别中扩增子阳性和扩增子阴性样本之间的RNA-Seq数据差异表达,并使用与上述类似的统计方法来确定显著的表达差异。该分析显示,在所有四种类型中,共有重叠区域内的七个基因与该扩增事件相关。此外,融合阳性RMS中有4个与扩增延伸区特异性相关的过表达基因,GBM、LAD和dLPS中有3个与扩增延伸区特异性相关的过表达基因。这些发现表明,细胞遗传学上相似的扩增事件实际上由一个共同的核心扩增区和特定癌症类别的额外扩展扩增区组成。我们之前对融合阳性RMS中2p24扩增事件的研究表明,MYCN被扩增并与该扩增子相关过表达。我们的研究证实了MYCN高表达在融合阳性RMS中的功能意义,我们发现外源性MYCN和PAX3-FOXO1的结合刺激了人成肌细胞的致癌转化和快速成瘤,尽管高MYCN和高PAX3-FOXO1表达不足以引起这些致癌作用。为了探索不同水平MYCN表达对MYCN的影响,并在实验中调节MYCN的表达,我们将MYCN cDNA和一个潮霉素抗性基因克隆到慢病毒强霉素诱导表达构建体中,设计了MYCN诱导表达构建体。结果表明,强力霉素可诱导高水平MYCN mRNA和蛋白在转导的成肌细胞中表达。然而,在没有强力霉素诱导的情况下,这些细胞的MYCN表达明显高于用空表达结构转导的细胞。这种低水平的泄漏足以在pax3 - fox01存在的情况下允许致癌转化。为了获得MYCN基础表达水平较低的转导细胞,我们进行了几个独立的转导实验,并分析了转导的重复,以找到MYCN基础表达最低的群体,然后从该群体中获得多个亚克隆。虽然在特定亚克隆中发现了非常低的MYCN基础表达,但随着细胞的传递,这种基础水平增加,这表明对高基础MYCN表达的强烈选择使这些计划的研究复杂化。
英文摘要
To extend our studies of the 12q13-q14 amplification in fusion-positive rhabdomyosarcoma (RMS), we used data from The Cancer Genome Atlas (TCGA) to compare our findings in RMS with amplification of this chromosomal region in other cancer categories. In particular, we identified multiple cases with 12q13-q14 amplification in glioblastoma multiforme (GBM), dedifferentiated liposarcoma (dLPS), and lung adenocarcinoma (LAC). Whereas our previous studies identified this amplicon in 25% of cases of PAX3-FOXO1-positive RMS, analysis of the TCGA data found 12q13-q14 amplification in 7% of LAC, 20% of GBM, and 86% of dLPS. We then used a statistical approach to delineate the consistently amplified region in each cancer category. In this analysis, a large genomic region surrounding the amplified region was split into numerous intervals, and the copy number in each interval was then assessed in amplicon-positive and amplicon-negative samples. Significant copy number differences in each interval were then evaluated by Mann-Whitney U tests with Bonferroni corrections. This analysis identified a common 0.24 Mb region of amplification (containing 13 genes, including CDK4) across the four cancer categories. In addition to the commonly amplified regions, the region of amplification extended in the centromeric direction in fusion-positive RMS and extended in the telomeric direction in GBM, dLPS, and LAC. To evaluate the expression consequences of these amplification events, RNA-Seq data was analyzed for differential expression between amplicon-positive and amplicon-negative samples in each of the cancer categories, and the similar statistical methods as described above were used to determine significant expression differences. This analysis revealed that seven genes within the common overlap region were overexpressed in association with this amplification event in all four categories. In addition, there were four overexpressed genes specifically associated with the extended region of amplification in fusion-positive RMS and three overexpressed genes specifically associated with the extended region of amplification in GBM, LAD, and dLPS. These findings indicate that cytogenetically similar amplification events actually consist of a common core amplified region and additional extended regions of amplification that are specific to certain cancer categories. Our previous studies of the 2p24 amplification event in fusion-positive RMS indicated that MYCN was amplified and over-expressed in association with this amplicon. The functional significance of high MYCN expression in fusion-positive RMS was demonstrated in studies in which we show that the combination of exogenous MYCN and PAX3-FOXO1 stimulated oncogenic transformation and rapid tumorigenesis of human myoblasts, though neither high MYCN nor high PAX3-FOXO1 expression was sufficient to cause these oncogenic effects. To explore the effect of different levels of MYCN expression and to modulate MYCN expression during experiments, we designed an inducible MYCN expression construct by cloning the MYCN cDNA and a hygromycin resistance gene into a lentiviral doxycycline-inducible expression construct. The resulting construct showed doxycycline induction of high levels of MYCN mRNA and protein in transduced myoblasts. However, in the absence of doxycycline induction, these cells showed significantly higher MYCN expression than cells transduced with the empty expression construct. This low level of leakiness was sufficient to permit oncogenic transformation in the presence of PAX3-FOXO1. To derive transduced cells with lower basal levels of MYCN expression, we performed several independent transduction experiments and analyzed the transduced replicates to find the population with the lowest basal MYCN expression and then obtained multiple subclones from this population. Though very low basal MYCN expression was found in specific subclones, this basal level increased as the cells were passed,indicating that there is a strong selection for high basal MYCN expression that complicated these planned studies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Studies of gene fusions in rhabdomyosarcoma
  • 批准号:
    10486830
  • 项目类别:
  • 资助金额:
    $70.45万
  • 财政年份:
    --
  • 负责人:
    Frederic Barr
  • 依托单位:
Studies of amplification in rhabdomyosarcoma
Studies of gene fusions in rhabdomyosarcoma
Studies of gene fusions in rhabdomyosarcoma
国内基金
海外基金
CTCF通过介导染色体13q14 基因组区异常构象促进视网膜母细胞瘤发生的机制研究
  • 批准号:
    81802739
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    21.0万元
  • 批准年份:
    2018
  • 负责人:
    文旭洋
  • 依托单位:
13q14染色体缺失通过下调miRNA表达参与多发性骨髓瘤血管新生
  • 批准号:
    30700331
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    17.0万元
  • 批准年份:
    2007
  • 负责人:
    孙春艳
  • 依托单位: